Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Wyeth Pharmaceuticals has unveiled new data showing that women who received 100mg/day or 150mg/day of desvenlafaxine, a serotonin and norepinephrine reuptake inhibitor, experienced a significant reduction in moderate to severe vasomotor symptoms like hot flashes and night sweats associated with menopause compared to those taking placebo.
Subscribe to our email newsletter
According to the company, this significant reduction was seen as early as week one. The common adverse drug reactions (greater than or equal to 5% of either desvenlafaxine group) in this study were asthenia, hypertension, anorexia (loss of appetite), constipation, diarrhea, dry mouth, nausea, dizziness, insomnia, somnolence and mydriasis.
Ginger Constantine, vice president of women’s healthcare at Wyeth Pharmaceuticals, said: “There are more than 10 million menopausal women who experience moderate to severe hot flashes and night sweats. Only a small percentage of menopausal women use FDA-approved treatments, all of which are hormone-based. Wyeth is committed to continuing to develop desvenlafaxine as a potential non-hormonal treatment option for women with moderate to severe vasomotor symptoms associated with menopause.”
David Archer, lead investigator of the 12-week study and professor in the Department of Obstetrics and Gynecology at Eastern Virginia Medical School, Clinical Research Center, added: “Additional treatment options are important for the millions of US women experiencing hot flashes and night sweats associated with menopause. Vasomotor symptoms can be quite disruptive for women in performing their daily activities.”